Depression in Alzheimer's disease: Epidemiology, mechanisms, and management

Journal of Alzheimer's Disease

Volumn 42, Issue 3, 2014, Pages 739-755

  Chi, Song ^a   Yu, Jin Tai ^a   Tan, Meng Shan ^b   Tan, Lan ^a,b  

^a QINGDAO UNIVERSITY   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

Alzheimer's disease; depression; epidemiology; mechanism; therapy

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; DOPAMINE; GLUTAMIC ACID; NEUROTROPHIN; NOOTROPIC AGENT; NORADRENALIN; SEROTONIN; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN DEPTH STIMULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COGNITIVE THERAPY; DEPRESSION; DIABETES MELLITUS; DIET THERAPY; DISEASE COURSE; DYSLIPIDEMIA; ENDOCRINE DISEASE; FOLLOW UP; HEREDITY; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INCIDENCE; INFLAMMATION; MULTISENSORY STIMULATION; MUSIC THERAPY; NEUROTROPHIN DEFICIENCY; PATHOLOGY; PREVALENCE; PROTEIN DEFICIENCY; RADIOELECTRIC ASYMMETRIC BRAIN STIMULATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SENSORY STIMULATION; SYSTEMATIC REVIEW; TRANSCUTANEOUS NERVE STIMULATION; COMPLICATION; DISEASE MANAGEMENT;

ALZHEIMER DISEASE; DEPRESSION; DISEASE MANAGEMENT; HUMANS; RISK FACTORS;

EID: 84907152157     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140324     Document Type: Review

References (160)

1. Engedal K, Barca ML, Laks J, Selbaek G (2011) Depression in Alzheimer's disease: Specificity of depressive symptoms using three different clinical criteria. Int J Geriatr Psychiatry 26, 944-951.
2. Benoit M, Berrut G, Doussaint J, Bakchine S, Bonin-Guillaume S, Frémont P, Gallarda T, Krolak-Salmon P, Marquet T, Mékiès C, Sellal F, Schuck S, David R, Robert P (2012) Apathy and depression in mild Alzheimer's disease: A cross-sectional study using diagnostic criteria. J Alzheimers Dis 31, 325-334.
3. Knapskog AB, Barca ML, Engedal K (2014) Prevalence of depression among memory clinic patients as measured by the Cornell Scale of Depression in Dementia. Aging Ment Health 18, 579-587.
4. Beeri MS, Werner P, Davidson M, Noy S (2002) The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 17, 403-408.
5. Campbell S, Marriott M, Nahmias C, MacQueen GM (2004) Lower hippocampal volume in patients suffering from depression: A meta-analysis. Am J Psychiatry 161, 598-607.
6. Namekawa Y, Baba H, Maeshima H, Nakano Y, Satomura E, Takebayashi N, Nomoto H, Suzuki T, Arai H (2013) Heterogeneity of elderly depression: Increased risk of Alzheimer's disease and A-protein metabolism. Prog Neuropsychopharmacol Biol Psychiatry 43, 203-208.
7. Sun X, Steffens DC, Au R, Folstein M, Summergrad P, Yee J, Rosenberg I, Mwamburi DM, Qiu WQ (2008) Amyloid-associated depression: A prodromal depression of Alzheimer disease Arch Gen Psychiatry 65, 542-550.
8. Lyketsos CG, Olin J (2002) Depression in Alzheimer's disease: Overview and treatment. Biol Psychiatry 52, 243-252.
9. Starkstein SE, Jorge R, Mizrahi R, Robinson RG (2005a) The construct of minor and major depression in Alzheimer's disease. Am J Psychiatry 162, 2086-2093.
10. Olin JT (2002) Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry 10, 125-128.
11. Vilalta-Franch J, Garre-Olmo J, López-Pousa S, Turon-Estrada A, Lozano-Gallego M, Hernández-Ferrándiz M, Pericot-Nierga I, Feijóo-Lorza R (2006) Comparison of different clinical diagnostic criteria for depression in Alzheimer disease. Am J Geriatr Psychiatry 14, 589-597.
12. Lee HB, Leyketsos CG (2003) Depression in Alzheimer's disease: Heterogeneity and related issues. Biol Psychiatry 54, 353-362.
13. Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Smith GE, Geda YE, Cummings JL, Petersen RC, Sunderland T (2003) A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry 160, 857-866.
14. Lyketsos CG, Steele C, Baker L, Galik E, Kopunek S, Steinberg M, Warren A (1997) Major and minor depression in Alzheimer's disease: Prevalence and impact. J Neuropsychiatry Clin Neurosci 9, 556-561.
15. Castilla-Puentes RC, Habeych ME (2010) Subtypes of depression among patients with Alzheimer's disease and other dementias. Alzheimers Dement 6, 63-69.
16. Newman SC (1999) The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample. J Affect Disord 52, 169-176.
17. Müller-Thomsen T, Arlt S, Mann U, Mass R, Ganzer S (2005) Detecting depression in Alzheimer's disease: Evaluation of four different scales. Arch Clin Neuropsychol 20, 271-276.
18. Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, Brayne C (2009) Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry 194, 212-219.
19. Wetzels RB, Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT (2010) Course of neuropsychiatric symptoms in residents with dementia in nursing homes over 2-year period. Am J Geriatr Psychiatr 18, 1054-1065.
20. Holtzer R, Scarmeas N, Wegesins in Alzheimer's disease: Natural course and temporal relation to function and cognitive status. J Am Geriatr Soc 53, 2083-2089.
21. Verkaik R, Nuyen J, Schellevis F, Francke A (2007) The relationship between severity of Alzheimer's disease and prevalence of comorbid depressive symptoms and depression: A systematic review. Int J Geriatr Psychiatry 22, 1063-1086.
22. Tagariello P, Girardi P, Amore M (2009) Depressive symptom depression and apathy in dementia: Same syndrome or different constructs A critical review. Arch Gerontol Geriatr 49, 246-249.
23. Mortby ME, Maercker A, Forstmeier S (2012) Apathy: A separate syndrome from depression in dementia A critical review. Aging Clin Exp Res 24, 305-316.
24. Payne JL, Sheppard JM, Steinberg M, Warren A, Baker A, Steele C, Brandt J, Lyketsos CG (2002) Incidence, prevalence, and outcomes of depression in residents of a long-term care facility with dementia. Int J Geriatr Psychiatry 17, 247-253.
25. van Vliet D, de Vugt ME, Aalten P, Bakker C, Pijnenburg YA, Vernooij-Dassen MJ, Koopmans RT, Verhey FR (2012) Prevalence of neuropsychiatric symptoms in young-onset compared to late-onset Alzheimer's disease-part 1: Findings of the two-year longitudinal NeedYD-study. Dement Geriatr Cogn Disord 34, 319-327.
26. Heun R, Kockler M, Ptok U (2002) Depression in Alzheimer's disease: Is there a temporal relationship between the onset of depression and the onset of dementia Eur Psychiatry 17, 254-358.
27. Weiner MF, Edland SD, Luszczynska H (1994) Prevalence and incidence of major depression in Alzheimer's disease. Am J Psychiatry 151, 1006-1009.
28. Weiner MF, Doody RS, Sairam R, Foster B, Liao TY (2002) Prevalence and incidence of major depressive disorder in Alzheimer's disease: Findings from two databases. Dement Geriatr Cogn Disord 13, 8-12.
29. Ballard CG, Patel A, Solis M, Lowe K, Wilcock G (1996) A one-year follow-up study of depression in dementia sufferers. Br J Psychiatry 168, 287-291.
30. Arbus C, GardetteV, Cantet CE, Andrieu S, Nourhashémi F, Schmitt L, Vellas B, REAL, Group FR (2011) Incidence and predictive factors of depressive symptoms in Alzheimer's disease: The REAL.FR study. J Nutr Health Aging 15, 609-617.
31. Li YS, Meyer JS, Thornby J (2001) Longitudinal follow-up of depressive symptoms among normal versus cognitively impaired elderly. Int J Geriatr Psychiatry 16, 718-727.
32. Wilson RS, Arnold SE, Beck TL, Bienias JL, Bennett DA (2008) Change in depressive symptoms during the prodromal phase of Alzheimer disease. Arch Gen Psychiatry 65, 439-445.
33. Wilson RS, Hoganson GM, Rajan KB, Barnes LL, Mendes de LeonCF,EvansDA(2010)Temporal course of depressive symptoms during the development of Alzheimer disease. Neurology 75, 21-26.
34. Devanand DP, Jacobs DM, Tang MX, Del Castillo-Castaneda C, Sano M, Marder K, Bell K, BylsmaFW, Brandt J, Albert M, Stern Y (1997) The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 54, 257-263.
35. Starkstein SE, Mizrahi R, Garau L (2005) Specificity of symptoms of depression in Alzheimer disease: A longitudinal analysis. Am J Geriatr Psychiatry 13, 802-807.
36. Kloszewska I (1998) Incidence and relationship between behavioural and psychological symptoms in Alzheimer's disease. Int J Geriatr Psychiatry 13, 785-792.
37. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006) Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63, 530-538.
38. Richard E, Reitz C, Honig LH, Schupf N, Tang MX,Manly JJ, Mayeux R, Devanand D, Luchsinger JA (2013) Latelife depression, mild cognitive impairment, and dementia. JAMA Neurol 70, 374-382.
39. Garcia-Garcýá P, de-la-Cámara C, Santabárbara J, Lopez-Anton R, Quintanilla MA, Ventura T, Marcos G, Campayo A, Saz P, Lyketsos C, Lobo A (2013) Depression and incident Alzheimer disease: The impact of disease severity. Am J Geriatr Psychiatry, doi: 10.1016/j.jagp.2013.02.011.
40. Geerlings MI, Schmand B, Braam AW, Jonker C, Bouter LM, van Tilburg W(2000) Depressive symptoms and risk of Alzheimer's disease in more highly educated older people. J Am Geriatr Soc 48, 1092-1097.
41. Olazarán J, Trincado R, Bermejo-Pareja F (2013) Cumulative effect of depression on dementia risk. Int J Alzheimers Dis 2013, 457175.
42. Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF, 3rd (2013) Late-life depression and risk of vascular dementia and Alzheimer's disease: Systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry 202, 329-335.
43. Heser K, Tebarth F, Wiese B, Eisele M, Bickel H, Köhler M, Mösch E, Weyerer S, Werle J, König HH, Leicht H, Pentzek M, Fuchs A, Riedel-Heller SG, Luppa M, Prokein J, Scherer M, Maier W, Wagner M, Age CoDe Study, Group (2013) Age of major depression onset, depressive symptoms, and risk for subsequent dementia: Results of the German Study on Ageing, Cognition, and Dementia in Primary Care Patients (AgeCoDe). Psychol Med 43, 1597-1610.
44. Lebedev AV, Beyer MK, Fritze F, Westman E, Ballard C, Aarsland D (2014) Cortical changes associated with depression and antidepressant use in Alzheimer and Lewy body dementia: An MRI surface-based morphometric study. Am J Geriatr Psychiatry 22, 4-13.
45. Son JH, Han DH, Min KJ, Kee BS (2013) Correlation between gray matter volume in the temporal lobe and depressive symptoms in patients with Alzheimer's disease. Neurosci Lett 548, 15-20.
46. O'Brien J, Perry R, Barber R, Gholkar A, Thomas A (2000) The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms. Ann N Y Acad Sci 903, 482-489.
47. Palmqvist S, Sarwari A, Wattmo C, Bronge L, Zhang Y, Wahlund LO, Nägga K (2011) Association between subcortical lesions and behavioral and psychological symptoms in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 32, 417-423.
48. Brommelhoff JA, Spann BM, Go JL, Mack WJ, Gatz M (2011) Striatal hypodensities, not white matter hypodensities on CT, are associated with late-onset depression in Alzheimer's disease. J Aging Res 2011, 187219.
49. Levy-Cooperman N, Burhan AM, Rafi-Tari S, Kusano M, Ramirez J, Caldwell C, Black SE (2008) Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease. J Psychiatry Neurosci 33, 218-226.
50. Kang JY, Lee JS, Kang H, Lee HW,Kim YK, Jeon HJ, Chung JK, Lee MC, Cho MJ, Lee DS (2012) Regional cerebral blood flowabnormalities associated with apathy and depression in Alzheimer disease. Alzheimer Dis Assoc Disord 26, 217-224.
51. Terada S, Oshima E, Sato S, Ikeda C, Nagao S, Hayashi S, Hayashibara C, Yokota O, Uchitomi Y (2014) Depressive symptoms and regional cerebral blood flow in Alzheimer's disease. Psychiatry Res 221, 86-91.
52. Holthoff VA, Beuthien-Baumann B, Kalbe E, Lüdecke S, Lenz O, Zündorf G, Spirling S, Schierz K, Winiecki P, Sorbi S, Herholz K (2005) Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression. Biol Psychiatry 57, 412-421.
53. Kataoka K, Hashimoto H, Kawabe J, Higashiyama S, Akiyama H, Shimada A, Kai T, Inoue K, Shiomi S, Kiriike N (2010) Frontal hypoperfusion in depressed patients with dementia of Alzheimer type demonstrated on 3DSRT. Psychiatry Clin Neurosci 64, 293-298.
54. Liao YC, Liu RS, Lee YC, Sun CM, LiuCY,Wang PS,Wang PN, Liu HC (2003) Selective hypoperfusion of anterior cingulate gyrus in depressed AD patients: A brain SPECT finding by statistical parametric mapping. Dement Geriatr Cogn Disord 16, 238-244.
55. Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, Hashimoto M, Yamashita H, Sasaki M (1998) Frontal lobe hypometabolism and depression in Alzheimer's disease. Neurology 50, 380-383.
56. Caraci F, Copani A, Nicoletti F, Drago F (2010) Depression and Alzheimer's disease: Neurobiological links and common pharmacological targets. Eur J Pharmacol 626, 64-71.
57. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455, 894-902.
58. Crochemore C, Lu J, Wu Y, Liposits Z, Sousa N, Holsboer F, Almeida OF (2005) Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry 10, 790-798.
59. Popp J, Schaper K, Kölsch H, Cvetanovska G, Rommel F, Klingmüller D, Dodel R, Wüllner U, Jessen F (2009) CSF cortisol in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 30, 498-500.
60. Notarianni E (2013) Hypercortisolemia and glucocorticoid receptor-signaling insufficiency in Alzheimer' s disease initiation and development. Curr Alzheimer Res 10, 714-731.
61. Hoogendijk WJ,Meynen G, Endert E, Hofman MA, Swaab DF (2006) Increased cerebrospinal fluid cortisol level in Alzheimer's disease is not related to depression. Neurobiol Aging 27, 780.e1-780.e2.
62. Zv¡e¡rová M, Fi¡sar Z, Jirák R, Kitzlerová E, Hroudová J, Raboch J (2013) Plasma cortisol in Alzheimer's disease with or without depressive symptoms. Med Sci Monit 19, 681-689.
63. Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW (2009) Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci USA 106, 18367-18372.
64. Rojo LE, Fernández JA, Maccioni AA, Jimenez JM, Maccioni RB (2008) Neuroinflammation: Implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39, 1-16.
65. Zhao J, O'Connor T, Vassar R (2011) The contribution of activated astrocytes to A-production: Implications for Alzheimer's disease pathogenesis. J Neuroinflammation 8, 150.
66. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2003) Altered gene expression of brainderived neurotrophic factor and receptor tyrosine kinaseBin postmortem brain of suicide subjects. Arch Gen Psychiatry 60, 804-815.
67. Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59, 1116-1127.
68. Aydemir O, Deveci A, Taneli F (2005) The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: A preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 29, 261-265.
69. Marano CM, Phatak P, Vemulapalli UR, Sasan A, Nalbandyan MR, Ramanujam S, Soekadar S, Demosthenous M, Regenold WT (2007) Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: A pilot study in patients with major depression. J Clin Psychiatry 68, 512-517.
70. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT (2001) Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 50, 260-265.
71. Dwivedi Y, Rizavi HS, Pandey GN (2006) Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: Differential regulation of specific exons by antidepressants and corticosterone. Neuroscience 139, 1017-1029.
72. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M (1997) Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res 49, 71-81.
73. Peng S, Wuu J, Mufson EJ, Fahnestock M (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the preclinical stages of Alzheimer's disease. J Neurochem 93, 1412-1421.
74. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15, 331-337.
75. Carroll JC, Iba M, Bangasser DA, Valentino RJ, James MJ, Brunden KR, Lee VM, Trojanowski JQ (2011) Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy. J Neurosci 31, 14436-14449.
76. Sotiropoulos I, Catania C, Pinto LG, Silva R, Pollerberg GE, Takashima A, Sousa N, Almeida OF (2011) Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits. J Neurosci 31, 7840-7847.
77. Dong H, Murphy KM, Meng L, Montalvo-Ortiz J, Zeng Z, Kolber BJ, Zhang S, Muglia LJ, Csernansky JG (2012) Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease. J Alzheimers Dis 28, 579-592.
78. Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM (2007) Acute stress increases interstitial fluid amyloidbeta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci USA 104, 10673-10678.
79. Colaianna M, Tucci P, Zotti M, Morgese MG, Schiavone S, Govoni S, Cuomo V, Trabace L (2010) Soluble beta amyloid(1-42): A critical player in producing behavioural and biochemical changes evoking depressive-related state Br J Pharmacol 159, 1704-1715.
80. Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M (2008) Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry 16, 168-174.
81. Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, Gorman JM, Haroutunian V (2006) Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 63, 161-167.
82. Wilson RS, Schneider JA, Bienias JL, Arnold SE, EvansDA, Bennett DA (2003) Depressive symptoms, clinical AD, and cortical plaques and tangles in older persons. Neurology 61, 1102-1107.
83. Skogseth R, Mulugeta E, Jones E, Ballard C, Rongve A, Nore S, Alves G, Aarsland D (2008) Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. Dement Geriatr Cogn Disord 25, 559-563.
84. Kramberger MG, Jelic V, K°areholt I, Enache D, Eriksdotter Jönhagen M, Winblad B, Aarsland D (2012) Cerebrospinal fluid alzheimer markers in depressed elderly subjects with and without Alzheimer's disease. Dement Geriatr Cogn Dis Extra 2, 48-56.
85. Ramakers IH, Verhey FR, Scheltens P, Hampel H, Soininen H, Aalten P, RikkertMO,VerbeekMM,Spiru L, BlennowK, Trojanowski JQ, Shaw LM, Visser PJ, Alzheimer's Disease Neuroimaging Initiative DESCRIPA, Investigators (2013) Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med 43, 911-920.
86. Zweig RM, Ross CA, Hedreen JC, Steele C, Cardillo JE, Whitehouse PJ, Folstein MF, Price DL (1988) The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 24, 233-242.
87. Zubenko GS, Moossy J (1988) Major depression in primary dementia. Clinical and neuropathologic correlates. Arch Neurol 45, 1182-1186.
88. Förstl H, Burns A, Luthert P, Cairns N, Lantos P, Levy R (1992) Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychol Med 22, 877-884.
89. Hendricksen M, Thomas AJ, Ferrier IN, Ince P, O'Brien JT (2004) Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. Am J Psychiatry 161, 1096-1102.
90. Chen CP, Eastwood SL, Hope T, McDonald B, Francis PT, Esiri MM (2000) Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol 26, 347-355.
91. Chen CP, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, Jobst KA, Francis PT (1996) Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: Correlations with depression and neuroleptic medication. J Neurochem 66, 1592-1598.
92. Marner L, Frokjaer VG, Kalbitzer J, Lehel S, Madsen K, Baaré WF, Knudsen GM, Hasselbalch SG (2012) Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease:Acombined [11C]DASB and [18F]altanserin-PET study. Neurobiol Aging 33, 479-487.
93. Ouchi Y, Yoshikawa E, Futatsubashi M, Yagi S, Ueki T, Nakamura K (2009) Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease. J Nucl Med 50, 1260-1266.
94. Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GW, Phelps ME (2006) Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci USA 103, 702-707.
95. Ackermann TF, Kempe DS, Lang F, Lang UE (2010) Hyperactivity and enhanced curiosity of mice expressing pkb/sgk-resistant glycogen synthase kinase-3 (gsk-3). Cell Physiol Biochem 25, 775-786.
96. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ,Wetsel WC, Gainetdinov RR, CaronMG(2008) Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 105, 1333-1338.
97. Pláteník J, Fi.sar Z, Buchal R, Jirák R, Kitzlerová E, Zv.e.rová M, Raboch J (2013) GSK3-, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression. Prog Neuropsychopharmacol Biol Psychiatry 50, 83-93.
98. Chan-Palay V, Asan E (1989) Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 287, 373-392.
99. Zubenko GS, Moossy J, Kopp U (1990) Neurochemical correlates of major depression in primary dementia. Arch Neurol 47, 209-214.
100. Stuerenburg HJ, Ganzer S, Müller-Thomsen T (2004) Hydroxyindoleacetic acid and homovanillic acid concentrations in cerebrospinal fluid in patients with Alzheimer's disease, depression and mild cognitive impairment. Neuro Endocrinol Lett 25, 435-437.
101. Mitchell RA, Herrmann N, Lanctôt KL (2011) The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS Neurosci Ther 17, 411-427.
102. Cummings JL, KauferD(1996) Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 47, 876-883.
103. Minger SL, Esiri MM, McDonald B, Keene J, Carter J, Hope T, Francis PT (2000) Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 55, 1460-1467.
104. Vermeiren Y, Le Bastard N, Van Hemelrijck A, Drinkenburg WH, Engelborghs S, De Deyn PP (2013) Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. Alzheimers Dement 9, 488-498.
105. Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB (1988) Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 12, 421-430.
106. Hashimoto K (2009) Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 6, 105-123.
107. Skolnick P, Popik P, Trullas R (2009) Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30, 563-569.
108. Pilc A, Wierónska JM, Skolnick P (2013) Glutamate-based antidepressants: Preclinical psychopharmacology. Biol Psychiatry 73, 1125-1132.
109. Tsang SW, Vinters HV, Cummings JL, Wong PT, Chen CP, Lai MK (2008) Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease. Neurobiol Aging 29, 1524-1532.
110. Zhao C, Deng W, Gage FH (2008) Mechanisms and functional implications of adult neurogenesis. Cell 132, 645-660.
111. Gao SF, Bao AM (2011) Corticotropin-releasing hormone, glutamate, and-aminobutyric acid in depression. Neuroscientist 17, 124-144.
112. Garcia-Alloza M, Tsang SW, Gil-Bea FJ, Francis PT, Lai MK, Marcos B, Chen CP, Ramirez MJ (2006) Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiol Aging 27, 1110-1117.
113. Valkanova V, Ebmeier KP (2013) Vascular risk factors and depression in later life: A systematic review and metaanalysis. Biol Psychiatry 73, 406-413.
114. Regan C, Katona C, Walker Z, Hooper J, Donovan J, LivingstonG(2006) Relationship of vascular risk to the progression of Alzheimer disease. Neurology 67, 1357-1362.
115. Taylor WD, Aizenstein HJ, Alexopoulos GS(2013) The vascular depression hypothesis: Mechanisms linking vascular disease with depression. Mol Psychiatry 18, 963-974.
116. Treiber KA, Lyketsos CG, Corcoran C, Steinberg M, Norton M, Green RC, Rabins P, Stein DM,Welsh-Bohmer KA, Breitner JC, Tschanz JT (2008) Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: The Cache County Study. Int Psychogeriatr 20, 538-553.
117. Moon Y, Kim H, Ok Kim J, Han SH (2013) Vascular factors are associated with the severity of the neuropsychiatric symptoms in Alzheimer's disease. Int J Neurosci 124, 512-517.
118. Purandare N,Voshaar RC, Hardicre J, Byrne J, McCollum C, Burns A (2006) Cerebral emboli and depressive symptoms in dementia. Br J Psychiatry 189, 260-263.
119. Steinberg M, Hess K, Corcoran C, Mielke MM, Norton M, Breitner J, Green R, Leoutsakos J, Welsh-Bohmer K, Lyketsos C, Tschanz J (2014) Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: The Cache County Study. Int J Geriatr Psychiatry 29, 153-159.
120. Luchsinger JA, Honig LS, Tang MX, Devanand DP (2008) Depressive symptoms, vascular risk factors, and Alzheimer's disease. Int J Geriatr Psychiatry 23, 922-928.
121. Panza F, Frisardi V, Seripa D, D'Onofrio G, Santamato A, Masullo C, Logroscino G, Solfrizzi V, Pilotto A (2012) Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. Ageing Res Rev 11, 87-103.
122. Zhang L, Fang Y, Zeng Z, Lian Y,Wei J, Zhu H, Jia Y, Zhao X, Xu Y (2011) BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response. J Alzheimers Dis 26, 523-530.
123. Borroni B, Grassi M, Archetti S, Costanzi C, Bianchi M, Caimi L, Caltagirone C, Di Luca M, Padovani A (2009) BDNF genetic variations increase the risk of Alzheimer's disease-related depression. J Alzheimers Dis 18, 867-875.
124. Arlt S, Demiralay C, Tharun B, Geisel O, Storm N, Eichenlaub M, Lehmbeck JT,Wiedemann K, Leuenberger B, Jahn H (2013) Genetic risk factors for depression in Alzheimer's disease patients. Curr Alzheimer Res 10, 72-81.
125. Grünblatt E, Zehetmayer S, Bartl J, Löffler C, Wichart I, Rainer MK, Jungwirth S, Bauer P, DanielczykW, Tragl KH, Riederer P, Fischer P (2009) Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITAstudy. J Psychiatr Res 43, 298-308.
126. Caraci F, Bosco P, Signorelli M, Spada RS, Cosentino FI, Toscano G, Bonforte C, Muratore S, Prestianni G, Panerai S, Giambirtone MC, Gulotta E, Romano C, Salluzzo MG, Nicoletti F, Copani A, Drago F, Aguglia E, Ferri R (2012) The CC genotype of transforming growth factor-1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression. Eur Neuropsychopharmacol 22, 281-289.
127. Holmes C, Arranz M, Collier D, Powell J, Lovestone S (2003) Depression in Alzheimer's disease: The effect of serotonin receptor gene variation. Am J Med Genet B Neuropsychiatr Genet 119B, 40-43.
128. Micheli D, Bonvicini C, Rocchi A, Ceravolo R, Mancuso M, Tognoni G, Gennarelli M, Siciliano G, Murri L (2006) No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. J Alzheimers Dis 10, 371-378.
129. Pritchard AL, Pritchard CW, Bentham P, Lendon CL (2007) Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord 24, 201-206.
130. Proitsi P, Lupton MK, Reeves SJ, Hamilton G, Archer N, Martin BM, Iyegbe C, Hollingworth P, Lawlor B, Gill M, Brayne C, Rubinsztein DC, Owen MJ, Williams J, Lovestone S, Powell JF (2012) Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol Aging 33, 791-803.
131. Liu HC, Hong CJ, Liu CY, Lin KN, Tsai SJ, Liu TY, Chi CW, Wang PN (2001) Association analysis of the 5-HT6 receptor polymorphism C267T with depression in patients with Alzheimer's disease. Psychiatry Clin Neurosci 55, 427-429.
132. Porcelli S, Salfi R, Politis A, Atti AR, Albani D, Chierchia A, Polito L, Zisaki A, Piperi C, Liappas I, Alberti S, Balestri M, Marsano A, Stamouli E, Mailis A, Biella G, Forloni G, Bernabei V, Ferrari B, Lia L, Papadimitriou GN, De Ronchi D, Serretti A (2013) Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. J Neural Transm 120, 1709-1715.
133. Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, Tariot PN, Blass DM, Steering Committee on Practice G, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty MT, Johnson BR, Nininger JE, Schneidman B, Summergrad P, Woods SM, Berger J, Cross CD, Brandt HA, Margolis PM, Shemo JP, Blinder BJ, Duncan DL, Barnovitz MA, Carino AJ, Freyberg ZZ, Gray SH, Tonnu T, Kunkle R, Albert AB, Craig TJ, Regier DA, Fochtmann LJ (2007) American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry 164, 5-56.
134. Modrego PJ (2010) Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment. J Alzheimers Dis 21, 1077-1087.
135. Thompson S, Herrmann N, Rapoport MJ, LanctôtKL(2007) Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: A metaanalysis. Can J Psychiatry 52, 248-255.
136. Banerjee S, Hellier J, DeweyM, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A,Walwyn R,Wilson K, Burns A (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): A randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378, 403-411.
137. Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A,Walwyn R,Wilson K, Burns A (2013) Study of the use of antidepressants for depression in dementia: The HTA-SADD trial-a multicentre, randomised, doubleblind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess 17, 1-166.
138. Weintraub D, Rosenberg PB, DryeLT,Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, DIADS-2 Research, Group (2010) Sertraline for the treatment of depression in Alzheimer disease: Week-24 outcomes. Am J Geriatr Psychiatry 18, 332-340.
139. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE,Weintraub D, PorsteinssonAP, Schneider LS, RabinsPV, Munro CA, Meinert CL, Lyketsos CG, DIADS-2 Research, Group (2010) Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18, 136-145.
140. Munro CA, Brandt J, Sheppard JM, Steele CD, Samus QM, Steinberg M, Rabins PV, Lyketsos CG (2004) Cognitive response to pharmacological treatment for depression in Alzheimer disease: Secondary outcomes from the depression in Alzheimer's disease study (DIADS). Am J Geriatr Psychiatry 12, 491-498.
141. Sepehry AA, Lee PE, Hsiung GY, Beattie BL, Jacova C (2012) Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: A metaanalysis of depression and cognitive outcomes. Drugs Aging 29, 793-806.
142. Mizukami K, Hatanaka K, TanakaY, Sato S, Asada T (2009) Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 33, 349-352.
143. Raji MA, Brady SR (2001) Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother 35, 1024-1027.
144. Lenze EJ, Skidmore ER, Begley AE, Newcomer JW, Butters MA, Whyte EM (2012) Memantine for late-life depression and apathy after a disabling medical event: A 12-week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry 27, 974-980.
145. Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS, Svetlik DA (2000) Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry 61, 487-492.
146. Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B, Donepezil MSAD, Study Investigators, Group (2002) Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 14, 389-404.
147. Cummings JL, McRae T, Zhang R, Donepezil-Sertraline Study, Group (2006) Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 14, 605-612.
148. Herrmann N, Rabheru K, Wang J, Binder C (2005) Galantamine treatment of problematic behavior in Alzheimer disease: Post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 13, 527-534.
149. Rösler M, Retz W, Retz-Junginger P, Dennler HJ (1998) Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 11, 211-216.
150. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL (2008) Efficacy of memantine on behavioral and psychological symptoms related to dementia: A systematic meta-analysis. Ann Pharmacother 42, 32-38.
151. Gauthier S, Loft H, Cummings J (2008) Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: A pooled data analysis. Int J Geriatr Psychiatry 23, 537-545.
152. Clerici F,Vanacore N, Elia A, Spila-Alegiani S, Pomati S,Da Cas R, Raschetti R, Mariani C, Memantine Lombardy Study, Group (2012) Memantine effects on behaviour in moderately severe to severe Alzheimer's disease:Apost-marketing surveillance study. Neurol Sci 33, 23-31.
153. Niu YX, Tan JP, Guan JQ, Zhang ZQ, Wang LN (2010) Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer's disease: A randomized controlled trial. Clin Rehabil 24, 1102-1111.
154. Mapelli D, Di Rosa E, Nocita R, Sava D (2013) Cognitive stimulation in patients with dementia: Randomized controlled trial. Dement Geriatr Cogn Dis Extra 3, 263-271.
155. Guétin S, Portet F, Picot MC, Pommié C, Messaoudi M, Djabelkir L, Olsen AL, Cano MM, Lecourt E, Touchon J (2009) Effect of music therapy on anxiety and depression in patients with Alzheimer's type dementia: Randomised, controlled study. Dement Geriatr Cogn Disord 28, 36-46.
156. Ozdemir L, Akdemir N (2009) Effects of multisensory stimulation on cognition, depression and anxiety levels of mildly-affected Alzheimer's patients. J Neurol Sci 283, 211-213.
157. Mannu P, Rinaldi S, Fontani V, Castagna A (2011) Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease. Clin Interv Aging 6, 207-211.
158. Luijpen MW, Swaab DF, Sergeant JA, Scherder EJ (2004) Effects of transcutaneous electrical nerve stimulation (TENS) on self-efficacy and mood in elderly with mild cognitive impairment. Neurorehabil Neural Repair 18, 166-175.
159. Freund-Levi Y, Basun H, Cederholm T, Faxén-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter-Jönhagen M (2008) Omega-3 supplementation in mild to moderate Alzheimer's disease: Effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23, 161-169.
160. O'Connor DW, Ames D, Gardner B, King M (2009) Psychosocial treatments of psychological symptoms in dementia: A systematic review of reports meeting quality standards. Int Psychogeriatr 21, 241-251.